Now more than ever, businesses, policymakers, investors and patients need real-time access to the data and analysis they need in order to navigate an industry that is no longer changing year by year – but week by week. Learn about how traditional cannabis industry data and insights are being transformed into a live, digital, and continuously evolving intelligence experience.

Eine mögliche Änderung des MedCan Gesetzes wirft einige Fragen auf. Wir besprechen, welche Anpassungen diskutiert werden, welche Auswirkungen diese auf die Versorgung und den Markt haben könnten und was das für diverse Stakeholder bedeutet.

As momentum for cannabis reform continues to shift across Europe, this panel will examine the evolving dynamics of cannabis policy at the EU level and beyond. Once seen as a catalyst for change, Germany\'s influence in pushing for EU-wide adult-use legalization has weakened, following a government reshuffle and a broader conservative turn in European politics. As a result, attempts to revise key frameworks have stalled, raising questions about the future of harmonized cannabis regulation across member states. Meanwhile, Switzerland, though outside the EU but within the Schengen Area, is moving ahead with adult-use legalization, offering a potential template for pragmatic and regulated models. Could Switzerland’s progress reignite momentum within the EU, prompting other countries to take bolder steps? This panel gathers legal, regulatory and industry voices to discuss whether national initiatives like Germany and Switzerland could trigger a wider domino effect: could their paths serve as a blueprint (or a political catalyst) for EU member states seeking to advance their own cannabis reforms amid growing legal and political complexity?

Unlike other medicines, communication and education pertaining to medical cannabis are confronted with unique challenges. Unique challenges require innovative approaches. Join us as we discuss how to navigate this unusual landscape effectively, what is being done as well as what needs to happen.

This keynote speech addresses the critical issue of \\\'GMP washing\\\', whereby cannabis flowers are given GMP status through minimal processing. It demonstrates how such practices can encourage mould growth and the production of highly toxic, heat-resistant mycotoxins that endanger patient safety. The presentation also reveals that decontaminating cannabis flos is an inadequate response to mycotoxin contamination, providing only ineffective damage control. Ultimately, it urges the industry to prioritise true pharmaceutical quality over profit-driven shortcuts, through robust prevention (GACP) and comprehensive testing.

Wie beeinflusst ein zunehmender Preisdruck die Wirtschaftlichkeit, die Qualität und Verfügbarkeit von medizinischen Cannabisblüten? In diesem Panel diskutieren wir, welche Auswirkungen dies auf die Patientenversorgung hat – und welche Wege es gibt, trotz wirtschaftlicher Zwänge eine sichere und hochwertige Versorgung zu gewährleisten.

The cannabis industry faces major challenges due to the lack of global definitions for medical and non-medical products, inconsistent use of terms like “CBD,” and unreliable labeling. Studies show discrepancies in CBD content, presence of THC, and contamination risks from pesticides and microbes. Further concerns arise from questionable lab testing practices and weak quality controls, especially in unregulated markets. This panel discussion will explore urgent questions: – Can cross-industry standards improve product safety and trust? – Should there be distinct requirements for consumer vs. patient products? – How can companies align with current standardization efforts? – Is globally consistent labeling and warnings feasible – and beneficial? – What are the advantages of a level playing field for all market participants? Join this panel to discuss how shared responsibility can shape a safer and more transparent future for cannabis.

Are we closer to a new cannabinoid finished pharmaceutical product? 2025 has included some promising developments. This panel will discuss both scientific developments and current market dynamics, as well as how far we are from a newly approved therapy and the implications looking ahead.

Medical Cannabis is booming in Germany, with the UK, Poland, and a number of other European countries not far behind. Telemedicine clinics are scaling in the UK, Switzerland and Germany, which resulted in imports into Germany to rise to 150 tons by 2025, a fourfold increase compared to 2023. “Prescription Shopping“, where medical cannabis platforms deploy physicians from EU-member states to issue medical cannabis prescriptions, is increasingly common. Do these developments suggest we now have recreational markets masquerading as Medical? Does the industry distinguish between patients and consumers? What are the risks, and what are the alternatives? The panel will discuss the “E-Commercification“ of Medical Cannabis, in Europe and the regulatory challenges this creates.

To spotlight the strategic leadership and operational success of women in cannabis – not as an ancillary health or wellness theme, but as a critical driver of the sector’s economic evolution. This panel addresses the real-world challenges and breakthroughs of female leaders and offers a blueprint for a more equitable, innovative, and profitable industry. Core Themes: – Breaking Barriers in Boardrooms Women are stepping into CEO, CFO, and COO roles across the global cannabis supply chain. We’ll discuss what it takes to get there and stay there. – Fundraising While Female Addressing the capital access gap, alternative financing strategies, and the systemic investor biases that continue to influence deal flow. – Scaling with Purpose How values-driven leadership (transparency, sustainability, community) is driving competitive advantage and long-term resilience. – Cultural Transformation How female leaders are rewriting outdated operational norms and building inclusive company cultures that retain top talent. – Beyond Representation From tokenism to transformation: building leadership pipelines that embed equity into the structure of the industry.

After two days packed with insights, inspiration, and bold ideas, our Closing Panel brings together the moderators of some of the many impactful sessions to reflect on the key takeaways from CB Conference. What trends emerged? Which challenges sparked the most debate? And what might lie ahead? Join us for this dynamic wrap-up moderated by Laura Ramos, as we spotlight the highlights, distill the facts, and close the conference with clarity and momentum.